Predictors of long-term renal outcome in lupus nephritis trials: Lessons learned from the euro-lupus nephritis cohort

Arthritis and Rheumatology

Volumn 67, Issue 5, 2015, Pages 1305-1313

  Dall'Era, Maria ^a   Cisternas, Miriam G ^b   Smilek, Dawn E ^c   Straub, Laura ^d   Houssiau, Frédéric A ^e   Cervera, Ricard ^f   Rovin, Brad H ^g   MacKay, Meggan ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MGC Data Services   (United States)

^c Immune Tolerance Network Lupus Nephritis Trials Network   (United States)

^d Immune Tolerance Network   (United States)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f UNIVERSITY OF BARCELONA   (Spain)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHYLPREDNISOLONE; BIOLOGICAL MARKER;

ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; ERYTHROCYTE URINE LEVEL; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; HEMATURIA; LONGITUDINAL STUDY; URINE;

BIOLOGICAL MARKERS; COHORT STUDIES; CREATININE; DISEASE PROGRESSION; GLUCOCORTICOIDS; HEMATURIA; HUMANS; LONGITUDINAL STUDIES; LUPUS NEPHRITIS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; ROC CURVE;

EID: 84928605460     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39026     Document Type: Article

References (24)

1. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, FitzGerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
2. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
3. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-4.
4. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.
5. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-95.
6. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
7. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014; 66: 379-89.
8. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69: 2083-9.
9. ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 2014; 66: 3096-104.
10. Wofsy D, Hillson JL, Diamond B., Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012; 64: 3660-5.
11. Wofsy D, Hillson JL, Diamond B., Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum 2013; 65: 1586-91.
12. Shapiro DE., The interpretation of diagnostic tests. Stat Methods Med Res 1999; 8: 113-34.
13. Fischer JE, Bachmann LM, Jaeschke R., A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29: 1043-51.
14. Christopher-Stine L, Petri M, Astor BC, Fine D., Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol 2004; 31: 1557-9.
15. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-32.
16. Bose B, Silverman ED, Bargman JM., Ten common mistakes in the management of lupus nephritis. Am J Kidney Dis 2014; 63: 667-76.
17. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D., Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken) 2011; 63: 351-7.
18. Cortes-Hernandez J, Torres-Salido MT, Medrano AS, Tarres MV, Ordi-Ros J., Long-term outcomes: mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010; 25: 3939-48.
19. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD, for the Lupus Nephritis Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904-14.
20. Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE., Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995; 4: 109-15.
21. Fraenkel L, MacKenzie T, Joseph L, Kashgarian M, Hayslett JP, Esdaile JM., Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. J Rheumatol 1994; 21: 2052-7.
22. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-40.
23. Rasoulpour M, Banco L, Laut JM, Burke GS., Inability of community-based laboratories to identify pathological casts in urine samples. Arch Pediatr Adolesc Med 1996; 150: 1201-4.
24. Kim Y, Jin DC, Lee EJ, Lee DH, Chung HH, Kim M, et al. Quantitative analysis of urine sediment using newly designed centrifuge tubes. Ann Clin Lab Sci 2002; 32: 55-60.